AHNS 10th International Conference on Head & Neck Cancer

Advance Program

AHNS 10th International Conference on Head and Neck Cancer
“Survivorship through Quality and Innovation”
July 22-25, 2021 | Virtual

*Program and Faculty Subject to Change
**All times are listed in Central Time

Thursday, July 22Friday, July 23Saturday, July 24Sunday, July 25
All Times Listed in Central Time Session Title
8:00am – 9:15am Opening Ceremony (NO CME)
Grant Achatz
Chef Grant Achatz is one of the most awarded and recognized chefs in the world. Known for his innovative, emotional, and modernist style of cuisine he has been named Best Chef in the United States by the James Beard Foundation, honored by Time Magazine as one of the 100 Most Influential People in the World, and has given talks and lectures on gastronomy and design at conferences and universities around the world.In 2004 Grant began building his dream restaurant, Alinea. Partnering with restaurant neophyte Nick Kokonas they sought to redefine fine dining in America, questioning not only culinary concepts but also the guest experience, tableware design, and restaurant bookings.
9:15am – 9:45am John J. Conley Lecture
Rebekah Gee, MD
Dr. Rebekah Gee is an Obstetrician/Gynecologist and CEO of Health Care Services for Louisiana State University. She recently served as Secretary of the Louisiana Department of Health, the state’s largest agency with a budget of $14 billion. In this cabinet role, her oversight responsibilities included Medicaid, Public Health, Disability Services, Behavioral Health, Aging and Adult Services, and disaster preparedness and response. While Secretary, Dr. Gee led the healthcare response to a variety of significant weather events as well as the response to infectious disease outbreaks such as Zika and Hepatitis A. Dr. Gee is a champion for healthcare coverage and was responsible for implementing the Medicaid expansion which extended coverage to over 500,000 Louisianans. She has led national policy discussions on the creation of affordable pharmaceuticals and developed a first in the nation elimination campaign for Hepatitis C spearheaded by her successful drug-pricing negotiations. As a result of this subscription model for individuals in Medicaid or who are incarcerated, more than ten times the number of Louisianans have been treated for Hepatitis C this year than in her first year as Secretary. She successfully eliminated a decades-long waitlist for individuals and families needing disability services by tailoring waiver services to recipient needs. Dr. Gee implemented an aggressive statewide opioid response plan, along with her statewide standing order for Naloxone, which has saved lives and been used by thousands of Louisianans. Dr. Gee led the charge to reduce maternal mortality and her efforts have resulted in a 39% reduction in complications due to heavy bleeding—the leading preventable cause of maternal death, and a 60% reduction in severe complications of pregnancy. Dr. Gee is a champion for health equity and created the South’s first Office of Health Equity in a state department of health.
9:45am – 10:30am Presidential Address and Awards
10:30am – 11:00am Break
11:00am – 12:20pm Controversial Topics in Thyroid Management
Moderators: Ashok Shaha, MD, Brendan Stack, MD
Panelists: Ellie Maghami, MD, Louise Davies, MD, MS, Elizabeth Blair, MD, Kerstin Stenson, MD, FACS
Schedule:

Case Presentation: Molecular Markers for Bethesda III and IV Lesions 11:00 am – 11:03 pm
Case Discussion 11:03 am – 11:13 pm
Case Presentation: Micro Carcinomas 11:13 am – 11:16 am
Case Discussion 11:16 am – 11:26 am
Case Presentation: RAI 11:26 am – 11:29 am
Case Discussion 11:29 am – 11:39 am
Case Presentation: Thyroid Cancer Lymphadenopathy 11:39 am – 11:42 am
Case Discussion 11:42 am – 11:52 am
Case Presentation: Anaplastic Thyroid Carcinoma  11:52 am – 11:55 am
Case Discussion 11:55 am – 12:05 pm
Case Presentation: Advanced Thyroid Cancer Surgery/Tracheal Involvement 12:05 pm – 12:08 pm
Case Discussion 12:08 pm – 12:20 pm

Description:
This session will outline what is currently known about the goals and relative priorities of head and neck cancer patients who have underwent treatment. Specific cases with real head and neck cancer survivors will be used to highlight common treatment-related side effects and approaches that can be used to help reduce short and long term toxicity.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Recognize common treatment-related side effects that impact head and neck cancer survivors.
  • Observe the relative priority survivors place on head and neck cancer cure compared to side effects from treatment.
  • Outline techniques that can be used to mitigate toxicity from head and neck cancer therapy.
11:00am – 12:20pm Management of Margins in Oral Cavity Cancer (NO CME)

Moderators: Mark Varvares, MD
Speakers & Schedule:

Introduction 11:00 am – 11:10 am
How to Avoid a Positive Margin – Terry Day, MD 11:10 am – 11:25 pm
Margin Analysis – a Surgeon`s Perspective – Stephan Kang, MD 11:25 am – 11:40 am
Oral Cavity Margin Assessment – a Pathologist`s Perspective – Margaret S. Brandwein-Weber 11:40 am – 11:55 am
Future Directions in Margin Management – Snehal Patel, MD, FRCS 11:55 am – 12:10 pm
Question and Answer – All Panelists 12:10 pm – 12:20 pm

Description:
Through a series of short lectures by nationally recognized experts on the topic we will address the key issues related to margin assessment in oral cancer resections.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Convey the key points in the discussion as to what constitutes a clear margin in oral cancer resections.
  • Employ surgical techniques so as to minimize the risk for a final positive margin.
  • Recognize what is on the horizon with respect to intraoperative guidance to decrease the risk of incomplete tumor resection.
12:20pm – 1:00pm Break
1:00pm – 1:50pm Controversies in the N0 Neck

Moderators: Stephen Lai, MD, PhD, FACS
Panelists: Kevin Robbins, MD, Sandeep Samant, MS, FRCS, Shaum Sridharan, Kelly Malloy, MD
Schedule:

Introduction/Background 1:00 pm – 1:05 pm
Case Study Presentation and Discussion 1:05 pm – 1:45 pm
Question and Answer 1:45 pm – 1:50 pm

Description:
A panel of experts will discuss the management of head and neck mucosal cancer patients with node-negative staging. The presentation will focus on case studies as the basis for discussion of currently available evidence and opportunities to investigate current questions and issues.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Understand the evolution of options available for management of the node-negative (N0) neck for head and neck mucosal cancer.
  • Evaluate the strengths and weaknesses of the available evidence regarding current treatment approaches for the N0 neck.
  • Identify opportunities to generate high-quality evidence related to treatment approaches for the N0 neck and the consequences of those options (e.g., quality of life, cost effectiveness).
1:00pm – 1:50pm Updates in Immunotherapy Trials

Moderators: Ezra Cohen, MD
Speakers & Schedule:

IO and HPV-Associated Cancers – Barbara Burtness, MD, A.B. Honors in Biology 1:00 pm – 1:07 pm
Neoadjuvant ChemolO Prior to Curative Chemoradiation – Aditya Juloori 1:07 pm – 1:14 pm
Neoadjuvant IO with Surgery for HPV-Negative Disease – Ravindra Uppaluri, MD, PhD 1:14 pm – 1:21 pm
How Should We Combine IO with Radiotherapy? – Kevin Harrington, MD 1:21 pm – 1:28 pm
Emerging IO Agents in HNSCC – Ezra Cohen, MD 1:28 pm – 1:35 pm
Panel Discussion & Question and Answer – All Panelists 1:35 pm – 1:50 pm

Description:
This session will update participants on how immunotherapy has been used in HNSCC, especially the locally advanced setting.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Appraise the current data on the use of immunotherapy in HNSCC.
  • Recognize potential strategies to integrate immunotherapy in HNSCC.
  • Articulate the challenges to using immunotherapy in HNSCC.
2:10pm – 3:00pm Controversies in Non-Melanoma Skin Cancer Management

Moderators: Cecelia Schmalbach
Speakers & Schedule:

Welcome/Overview – Cecelia Schmalbach, MD, MSc, FACS 2:10 pm – 2:15 pm
Objective #1 – Sue Yom, MD 2:15 pm – 2:27 pm
Objective #2 – Dan Zanderg, MD 2:27 pm – 2:39 pm
Objective #3 – David Cognetti, MD 2:39 pm – 2:51 pm
Question and Answer – All Panelists 2:51 pm – 3:00 pm

Description:
This interactive panel brings together leading specialists from Radiation Oncology, Medical Oncology and Otolaryngology-HNS to provide evidence-based answers to controversies surrounding the management of advanced NMSC. 3 tumor board style cases with interactive polling will provide rich discussion surrounding adjuvant radiation for surgically resected cSCC, PD-1 systemic therapy for BCC and cSCC, and optimal management of Merkel Cell Carcinoma.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Demonstrate understanding of the role for adjuvant radiation for surgically resected advanced NMSC.
  • Explain the indications for PD-1 inhibitor systemic use for advanced BCC and SCC.
  • Outline Merkel cell carcinoma treatment options with respect to sentinel node biopsy, selective neck dissection and radiation therapy.
2:10pm – 3:00pm Battleground Oropharynx: Photons, Protons, Lasers, and Robots

Moderators: Chris Holsinger, MD
Speakers & Schedule:

Introduction – Chris Holsinger, MD 2:10 pm – 2:12 pm
Radiation Oncology Pearls & Pitfalls – Sharon Spencer, MD 2:12 pm – 2:17 pm
Descalation of Treatment with Surgery – Umamaheswar Duvvuri, MD, PhD 2:17 pm – 2:22 pm
The Unknown Primary: `Search & Rescue’ – Bruce Haughey, MBChB, FACS, FRACS 2:22 pm – 2:27 pm
Surgery for Oropharyngeal Cancer: What are we Arguing and Debating in Tumor Board – Gady Har-El, MD 2:27 pm – 2:32 pm
Case Discussion #1 – All Panelists 2:32 pm – 2:37 pm
Case Discussion #2 – All Panelists 2:37 pm – 2:47 pm
Case Discussion #3 – All Panelists 2:47 pm – 2:57 pm
Closing – Chris Holsinger 2:57 pm – 3:00 pm

Description:
Pre-operative decision-making and patient selection have a significant influence of post-op adjuvant care and thus overall functional outcomes. Yet there is a lack of consensus about what these pre-operative decision-making criteria are. Which patients are best for surgery? Which for radiation? Should some patients have TLM? In this multidisciplinary panel, experts present a series of 3-5 min rapid-fire “pearls and pitfalls” presentations, then we spend more than half the session managing both routine and challenging cases, including: a T2 N0 SCC left tonsil ; 49 yo M never smoker ; T1 N1 SCC midline tongue-base 75 yo M never smoker (tumor = midline); T0 N1 SCC p16+ presumed oropharynx
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Identify which patients with oropharyngeal cancer are best suited for surgery.
  • Discuss indications for post-operative adjuvant therapy for patients with oropharyngeal cancer treated with transoral endoscopic H&N surgery (TORS or TLM).
  • Formulate the current approach to identifying and managing the unknown primary SCC metastatic to the neck.
3:00pm – 3:30pm Break
3:30pm – 4:20pm Controversies in Reconstructive Surgery

Moderators: Mark Wax, MD & Daniel Deschler, MD, FACS
Panelists: Richard Hayden, MD Liana Puscas, MD, D. Gregory Farwell, MD, FACS
Schedule:

Case Presentation – Mark Wax, MD 3:30 pm – 3:32 pm
Panel Discussion – All Panelists 3:32 pm – 3:47 pm
Case Presentation – Daniel Deschler, MD, FACS 3:47 pm – 3:49 pm
Panel Discussion – All Panelists 3:49 pm – 4:04 pm
Case Presentation – Mark Wax, MD 4:04 pm – 4:06 pm
Panel Discussion – All Panelists 4:06 pm – 4:20 pm

Description:
We will use a case management format to discuss controversial reconstructive issues: Free tissue transfer for scalp reconstruction versus Integra, early stage hemi-glossectomy with a radial forearm versus regional flap, the role of 3D modeling for simple and complex maxillofacial reconstruction.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Distinguish the difference soft tissue options available for tongue reconstruction.
  • Discussed the difference in wound healing with free tissue transfer versus Integra.
  • Integrate 3D modeling into complex maxillofacial reconstruction.
3:30pm – 4:20pm Laryngeal Cancer – Controversies

Moderators: Bevan Yueh, MD
Speakers & Schedule:

Case Presentation #1 – Bevan Yueh, MD 3:30 pm – 3:32 pm
Case Discussion with Panel – Richard Smith, MD 3:32 pm – 3:42 pm
Case Presentation #2 – Bevan Yueh, MD 3:42 pm – 3:44 pm
Case Discussion with Panel – Jimmy Caudell 3:44 pm – 3:54 pm
Case Presentation #3 – Bevan Yueh, MD 3:54 pm – 3:56 pm
Case Discussion with Panel – Saad Khan, MD 3:56 pm – 4:06 pm
Case Presentation #4 – Bevan Yueh, MD 4:06 pm – 4:08 pm
Case Discussion with Panel – Brian Burkey, MD, MEd, FACS 4:08 pm – 4:20 pm

Description:
We will use case discussions to highlight controversies in the treatment of laryngeal cancer, including the management of new primary tumors, recurrent and persistent disease, and complications after treatment. The panelists will provide 1-2 take-home points on each case.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Appraise treatment options for locoregional new primary and recurrent tumors of laryngeal cancer.
  • Determine indications for the use of immunotherapy in the recurrent setting.
  • Recognize diagnostic and treatment dilemmas in the management of complications such as osteoradionecrosis.
4:40pm – 5:30pm Video Session: Experts in Surgical Technique – Head and Neck

Moderators: Sarah Rohde
Speakers & Schedule:

Neck Dissection – William Carroll, MD 4:40 pm – 4:55 pm
Oral Cavity Resection – Claudio Cernea, MD 4:55 pm – 5:10 pm
Robotic Oropharyngeal Resection – Gregory Weinstein, MD 5:10 pm – 5:25 pm
Question and Answer – All Panelists 5:25 pm – 5:30 pm

Description:
This session will use video to review technique related to oral cavity resection, neck dissection and robotic oropharyngeal resection. Participants will learn standard techniques plus pearls from experts in each area.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Articulate key steps in neck dissection, oral cavity resection and robotic oropharyngeal resection.
  • Develop approaches to common challenges in the surgical treatment of squamous cell carcinoma.
  • Integrate surgical pearls into future cases.
4:40pm – 5:30pm Health Disparities in Modern Head and Neck Practice: How Can We Do Better? (Women in AHNS)

Moderators: Amy Chen, MD, MPH & Kelly Malloy, MD
Speakers & Schedule:

Introduction – Amy Chen, MD, MPH 4:40 pm – 4:55 pm
Case 1: Socioeconomic/Racial Disparities – Kelly Malloy, MD 4:55 pm – 5:10 pm
Case 1: Socioeconomic/Racial Disparities – Gina Jefferson, MD 5:10 pm – 5:25 pm
Case 1: Socioeconomic/Racial Disparities – Leila Mady, MD PhD MPH, Finance and Chemistry (minor)
5:25 pm – 5:30 pm
Case 2: Clinical Trials – Kelly Malloy, MD 4:40 pm – 4:55 pm
Case 2: Clinical Trials – Nicole Schmitt, MD 4:55 pm – 5:10 pm
Case 3: Access to Care – Amy Chen, MD, MPH 5:10 pm – 5:25 pm
Case 3: Access to Care – Antoine Eskander, MD, ScM, FRCSC 5:25 pm – 5:30 pm
Discussion with Audience – All Panelists 5:25 pm – 5:30 pm

Description:
We will use a case management format to discuss four aspects of disparities: clinical trial disparities, racial-ethnic-socioeconomic disparities, and access to care disparities.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Predict important socioeconomic, racial, and ethnic disparities that may impact your patients’ care.
  • Identify barriers to clinical trials participation.
  • Advocate effectively for your patients to achieve equity in care.
6:00pm – 7:00pm Industry Symposia – Cardinal Health & Sanofi Genzyme
All Times Listed in Central Time Session Title
7:30am – 8:30am Jatin Shah Symposium: De-escalation Therapy – What it Means for Patient Care Today

Moderators: Robert Ferris, MD, PhD
Speakers & Schedule:

Rationale and History for Treatment Deintensification – Robert Ferris, MD, PhD 7:30 am – 7:34 am
Controversies in Transoral Surgery with De-escalation – Jeremy Richmon, MD, FACS 7:34 am – 7:42 am
Results of Surgical Deintensification Trials Including ECOG-3311, PATHOS, and ORATOR – Neil Gross, MD, FACS 7:42 am – 7:50 am
Results of Prospective Trials of Radiation Dose and Field Deintensification for Good Prognosis Disease – Aditya Juloori 2:50 am – 7:58 am
Use of Induction Therapy to Identify Good Prognosis Patients (Chemo Selection) for Reduced Dose Concurrent Therapy – Everett E. Vokes, MD 7:58 am – 8:06 am
Putting It All Together, Selecting the Right Patient for the Right Intensity Therapy at the Right Time and The Future Head to Head Comparative Phase III Trials – Barbara Burtness, MD, A.B. Honors in Biology 8:06 am – 8:14 am
Case Based Discussion – All Panelists 8:14 am – 8:30 am

Description:
With the greater understanding of risk stratification including the identification of HPV+ oropharynx cancer and its dramatically better prognosis, attention has focused on developing level 1 evidence in favor of reduced intensity therapy to promote survivorship and reduce treatment related toxicities. This symposium will report on recently completed and ongoing prospective clinical trials aimed at reducing toxicity of conventional therapies as well as identifying good prognosis, low-risk populations who are most appropriate for this type of therapy.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Identify risk stratification categories to distinguish low-risk populations particularly HPV+ oropharynx cancer patients who are candidates for reduced intensity therapy.
  • Describe reported and ongoing strategies for reducing chemotherapy, radiation therapy, and/or surgical therapy based on prospective randomized trials and results.
  • Discuss oncologic outcomes to date and functional and quality of life endpoints from prospective trials of de-intensified therapy.
8:45am – 9:30am Keynote Address
Otis Webb Brawley, MD, MACP, FRCP, FASCO, FACE
Otis Webb Brawley is a medical oncologist and epidemiologist. He serves as Bloomberg Distinguished Professor in the Department of Oncology of the School of Medicine and the Department of Epidemiology in the Bloomberg School of Public Health at Johns Hopkins University. He is a member of the National Cancer Institute Board of Scientific Advisors and the National Academy of Medicine.From 2007 to 2018, Brawley was Chief Medical and Scientific Officer of the American Cancer Society. From that position, he oversaw the largest private cancer research funding program in the U.S. He previously served as a professor in the Emory University School of Medicine and the Rollins School of Public Health and as a tenured senior investigator at the National Cancer Institute.Among numerous awards, he received the Key to St. Bernard Parish for his work in the U.S. Public Health Service in the aftermath of Hurricane Katrina. He is a Master of the American College of Physicians, a Fellow of the Royal College of Physicians (London), a Fellow of the American Society of Clinical Oncology, and a Fellow of the American College of Epidemiology. Brawley graduated from the University of Chicago, Pritzker School of Medicine.
9:45am – 10:30am Hayes Martin Lecture
James Netterville, MD
James L. Netterville, M.D. is the Mark C. Smith Professor, Director of Head and Neck Oncologic Services and Executive Vice Chair of Vanderbilt’s Department of Otolaryngology – Head and Neck Services, and Associate Director of the Bill Wilkerson Center for Otolaryngology and Communication Sciences. He is past President of the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS). His primary interests are Head and neck oncologic surgery, Endocrine surgery, skull base surgery, with special interest in the management of Head & Neck paragangliomas, Tumors of the parapharyngeal space, recurrent/persistent Thyroid cancer, as well as enucleation of schwannomas of major cranial nerves . His research interests are in the areas of robotic development, cranial nerve rehabilitation, baro-reflex failure, and clinical outcomes. For the last 21 years he as lead and participated in medical educational outreach with efforts in Kenya, Nigeria, Uganda, and Haiti. The emphasis of these collaborative outreach trips is education, capacity building, and collection of educational and patient care outcomes. He has been on Faculty at Vanderbilt since 1986, which has offered him the rare opportunity to train over 150 Otolaryngology HNSurg. residents, and 54 Head & Neck surgical oncology Fellows. He is most proud of his “Medical Children” and all they have accomplished to make this world a much better place.
10:30am – 11:00am Break
11:00am – 12:20pm Reducing the Burden – Improving Quality of Life in Survivorship

Moderators: Carole Fakhry, MD, MPH
Speakers & Schedule:

Welcome and Introduction – Carole Fakhry, MD, MPH 11:00 am – 11:05 am
The Importance of Survivorship – Michael Moore, MD 11:05 am – 11:20 am
How Do We Measure Success? – Wayne Koch, MD 11:20 am – 11:35 am
What is Needed for a Successful Survivorship Program? – Steven Cannady 11:35 am – 11:50 am
Multidisciplinary Survivorship Care: An Institutional Perspective – Melonie Nance, MD 11:50 am – 12:05 pm
Discussion/Question and Answer – All Panelists 12:05 pm – 12:20 pm

Description:
Increasingly, quality of life and treatment-related toxicity, in addition to cancer cure, are being recognized as priorities for those undergoing head and neck cancer treatment. This session will outline evidence to support the development of survivorship programs and metrics used to assess quality of life and function after head and neck cancer treatment as well as aspects that are important in order to develop a successful survivorship program.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Outline evidence to support the development of head and neck cancer survivorship programs.
  • Describe evidence-based tools to measure important survivorship metrics such as distress, swallowing function and quality of life.
  • Outline key components necessary for implementing a successful head and neck cancer survivorship program.
11:00am – 12:20pm Oropharynx Cancer Debate

Moderators: Bert O’Malley, MD
Speakers & Schedule:

Oropharynx Cancer Case 1 – Hisham Mehanna, PhD, MD 11:00 am – 11:15 am
Oropharynx Cancer Case 2 – Christine Chung 11:15 am – 11:30 am
Oropharynx Cancer Case 3 – Andy Clump 11:30 am – 11:45 am
Oropharynx Cancer Case 4 – Matthew Old, MD 11:45 am – 12:00 pm
Question and Answer – All Panelists 12:00 pm – 12:20 pm

Description:
We will use a case presentation and management format to facilitate conversation and debate as to the various options for managing patients with Oropharynx Cancer. With our session faculty, we bring together a combination of surgical expertise, radiation expertise, and chemotherapy expertise and will present cases that stimulate discussion as to the optimal treatment algorithms for patients with oropharyngeal cancer.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Demonstrate an in depth understanding of the various treatment options for orpharyngeal cancer.
  • Recognize the benefit and weaknesses of the various treatment options as they relate to outcomes for oropharyngeal cancer.
  • Develop the decision making strategy for informing patients about their treatment options and making the optimal and personalized treatment plan.
12:20pm – 1:00pm Break
1:00pm – 1:50pm Advanced Thyroid Cancer Tumor Board

Moderators: Mark Zafereo, MD
Panelists: Joseph Scharpf, MD, FACS, Lori Wirth, Miriam Lango, MD, William Armstrong, MD
Schedule:

Introduction 3:30 pm – 3:32 pm
Case Presentation #1 with Panel Discussion 3:32 pm – 3:47 pm
Case Presentation #2 with Panel Discussion 3:47 pm – 3:49 pm
Case Presentation #3 with Panel Discussion 3:49 pm – 4:04 pm

Description:
We will use a case presentation format to discuss novel therapeutics and multidisciplinary treatment strategies in the management of advanced thyroid cancer including aggressive differentiated thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Identify novel targeted systemic therapy strategies for advanced thyroid cancer.
  • Relate how multidisciplinary treatment strategies may be integrated with surgery for optimal management of patients with advanced thyroid cancer.
  • Discuss surgical complexities, challenges, and decision-making in advanced thyroid cancer.
1:00pm – 1:50pm Proffered Papers 1: Skull Base Plus
Moderators: Andrew Birkeland, MD, Rusha Patel & Heath Skinner, MD
(S001) INTRA-OPERATIVE FROZEN SECTION HISTOPATHOLOGY IN SINONASAL AND SKULL BASE TUMORS: A SINGLE INSTITUTION EXPERIENCE.
Tim Mclean, MBBS; Conall Fitzgerald, MBBCh; Avery Yuan, MB, MMCi; Snehal Patel, MD; Snjezana Dogan, MD; Ian Ganly, MD, PHD; Marc Cohen, MD, MPH; Memorial Sloan Kettering Cancer Center
(S002) ENDOSCOPIC CT-NAVIGATED INTRAOPERATIVE MAPPING BIOPSIES OF THE CRANIAL BASE IN THE MANAGEMENT OF RECURRENT NASOPHARYNGEAL CANCER.
Peter Costantino, MD, FACS1; Rakhna Araslanova, MD, FRCSC1; Tristan Tham, MD2; 1New York Head and Neck Institute; 2Zucker School of Medicine at Hofstra/Northwell, New York,NY
(S003) ASSESSING THE RELATIONSHIP BETWEEN SUVMAX, GENOMIC PROFILE AND SURVIVAL IN HEAD & NECK CANCER PATIENTS RECEIVING IMMUNOTHERAPY
Conall W Fitzgerald, MD; Cristina Valero, MD; Christina E Swartzwelder, RPAC; Luc G Morris, MD; Memorial Sloan Kettering Cancer Center
(S004) SYSTEMIC INFLAMMATION IS ASSOCIATED WITH DISEASE EXTENT AND SURVIVAL IN ORAL CAVITY SQUAMOUS CELL CARCINOMA
Brendan Coutu, MD; Dallin Christensen, MD; Evan Ryan, BS; Elizabeth Bradford Bell, MD; Weining Zhen, MD; Zafar Sayed, MD; University of Nebraska Medical Center
(S005) YOUNG NON-SMOKERS WITH ORAL CANCER: WHAT ARE WE MISSING AND WHY?
Cristina Valero1; Avery Yuan1; Daniella K Zanoni1; Snjezana Dogan2; Jatin P Shah1; Luc G Morris1; Richard J Wong1; Aviram Mizrachi3; Snehal G Patel1; Ian Ganly1; 1Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Department of Otorhinolaryngology – Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel
(S006) PRACTICE PATTERNS IN TRANSORAL ROBOTIC SURGERY: RESULTS OF AN AMERICAN HEAD AND NECK SOCIETY SURVEY
Andrew J Holcomb, MD1; Rachael Kammer, CCCSLP1; Allison Holman, CCCSLP1; Tessa Goldsmith, CCCSLP1; Vasu Divi, MD2; Heather M Starmer, CCCSLP2; Joseph Zenga, MD3; Ryan Li, MD4; Urjeet A Patel, MD5; Jeremy D Richmon, MD1; 1Massachusetts Eye and Ear / Harvard Medical School; 2Stanford University; 3Medical College of Wisconsin; 4Oregon Health Sciences University; 5Northwestern University
2:10pm – 3:00pm Management of Salivary Gland Tumors

Moderators: Patrick Ha, MD, FACS 
Speakers & Schedule:

Introduction – Patrick Ha, MD, FACS 2:10 pm – 2:13 pm
Optimal Imaging for Staging and Surveillance of Salivary Gland Tumors – Barton Branstetter, IV, MD 2:13 pm – 2:18 pm
Extent of Parotidectomy and the Role of Extracapsular Dissection – Marita Teng, MD, FACS 2:18 pm – 2:23 am
Retrograde Approach for Parotid Tumors – Davud Sirjani, MD 2:23 pm – 2:28 pm
Reconstruction of Parotid Defects – Danny Enepekides, MD, FRCS 2:28 am – 2:33 pm
Targeted Therapy for Salivary Gland Malignancies – Alexander Colevas, MD 2:33 pm – 2:38 pm
Case Presentation and Discussion – All Panelists 2:38 pm – 3:00 pm

Description:
We will use concise lectures to cover high-yield topics in the management of salivary gland tumors, as well as case-based presentations to help provide practical guidance in patient care.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Develop a surgical plan for the removal and reconstruction of parotid tumors.
  • Employ appropriate imaging for staging and surveillance of salivary tumors.
  • Integrate the use of systemic treatment for salivary gland malignancies.
2:10pm – 3:00pm Proffered Papers 2: Function/Quality
Moderators: Natalya Chernichenko, MD, David Neskey, MD & Kristen B. Pytynia, MD, MPH
(S007) BUILDING A QUALITY AND VALUE REPORTING DATABASE FOR HEAD AND NECK ONCOLOGIC SURGERY
Vasu Divi, MD1; Evan Graboyes2; Carol M Lewis3; John De Almeida4; Christine Gourin5; Amy Anne D Lassig6; Andres Bur7; Scharukh Jalisi8; Andrew C Birkland9; Trevor Hackman10; Carissa Thomas11; John Cramer12; Ryan Li13; Andrew Larson14; Ameya Asarkar15; James Hamilton16; Paul Van der Sloot17; Ashley Mays18; Mohammad Akheel19; John Pang20; Daniel Pinheiro21; Avinash Mantravadi22; Nader Sadeghi23; Terry Tsue7; 1Stanford University; 2Medical University of South Carolina; 3MD Anderson; 4University of Toronto; 5Johns Hopkins University; 6University of Minnesota; 7University of Kansas Medical Center; 8Beth Israel Deaconess Medical Center; 9University of California Davis; 10University of North Carolina; 11University of Alabama Medical Center; 12Wayne State University; 13Oregon Health Sciences University; 14Massachusetts Eye and Ear Infirmary; 15Louisiana State University Shreveport; 16Emory University; 17Swedish Medical Center Denver; 18Louisiana State University Baton Rouge; 19Head & Neck Cancer Hub, Indore; 20University of Washington; 21Mercy Head & Neck Cancer; 22Indiana University; 23McGill University
(S008) SURGICAL MARGIN TRENDS FOLLOWING TOTAL LARYNGECTOMY: A HOSPITAL BASED STUDY
John Pang, MD1; Farhoud Faraji, MD2; Emily Robinson1; Harrison Cash, MD1; Brittany Barber, MD1; Neal Futran, MD1; Zain Rizvi, MD1; Jeffrey Houlton, MD1; 1University of Washington; 2University of California – San Diego
(S009) SUICIDE INCIDENCE AND RISK AMONG HEAD AND NECK CANCER SURVIVORS BASED ON URBAN VS. RURAL RESIDENCE STATUS
Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES1; Justin M Barnes, MD, MS2; Somtochi Okafor, MD1; Derian B Taylor, BS3; Adnan S Hussaini, MD4; Eric Adjei Boakye, PhD5; Matthew C Simpson, MPH3; Evan M Graboyes, MD, MPH6; Trinitia Cannon, MD1; Walter T Lee, MD, MS1; 1Duke University School of Medicine; 2Washington University in St. Louis; 3Saint Louis University School of Medicine; 4George Washington University; 5Southern Illinois University School of Medicine; 6Medical University of South Carolina
(S010) MANUAL THERAPY FOR FIBROSIS-RELATED LATE EFFECT DYSPHAGIA IN HEAD AND NECK CANCER SURVIVORS: PRELIMINARY RESULTS OF THE PILOT MANTLE TRIAL
Katherine A Hutcheson, PhD; Holly McMillan, MCD, LMP, CLT; Christine Porsche-Bockeloh, MS, CLT; Kiara Savage, MS, CLT; Sheila Buoy, MPH; C. D Fuller, MD, PhD; Stephen Y Lai, MD, PhD; Karin Woodman, MD; Carly A Barbon, PhD; Carla L Warneke, MS; The University of Texas MD Anderson Cancer Center
(S011) PERI-OPERATIVE PAIN, OPIOID USE, AND OPIOID PRESCRIPTIONS FOLLOWING INPATIENT HEAD AND NECK CANCER SURGERY
Danielle R Trakimas, MD, MSE; Rajarsi Mandal, MD; Marietta Tan, MD; Christine G Gourin, MD, MPH; Carole Fakhry, MD, MPH; Wayne M Koch, MD; Jonathon O Russell, MD; Ralph P Tufano, MD; David W Eisele, MD; Peter S Vosler, MD, PhD; Johns Hopkins Hospital
(S012) RISK FACTORS OF PATIENT-REPORTED FATIGUE AMONG LONG-TERM OROPHARYNGEAL CANCER SURVIVORS
Puja Aggarwal, PhD, BDS, MPH1; Katherine A Hutcheson1; Ryan P Goepfert1; Adam S Garden1; Frank E Mott1; Clifton D Fuller1; Stephen Y Lai1; G. Brandon Gunn1; Ehab Y Hanna1; Erich M Sturgis2; 1MD Anderson; 2Baylor College of Medicine
3:00pm – 3:30pm Break
3:30pm – 4:20pm Current Concepts in Speech and Swallow Rehabilitation

Moderators: Katherine Hutcheson, MD
Panelists: Heather Starmer, MA, Dinesh Chhetri, MD, Rosemary Martino, PhD
Schedule:

Introduction 3:30 pm – 3:40 pm
Case Presentation 1 with Panel Discussion 3:40 pm – 4:00 pm
Case Presentation 2 with Panel Discussion 4:00 pm – 4:20 pm

Description:
Interdisciplinary panelists will use a case based approach illustrating contemporary issues in speech and swallowing rehabilitation. Behavioral, medical, and surgical therapies will be discussed across diverse disease sites and treatment scenarios balancing considerations from diagnosis through long-term survivorship.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Develop proactive speech and swallowing rehabilitation protocols for surgical and non-surgical treatment settings.
  • Distinguish surgical management options based on dysphagia pathophysiology.
  • Describe models of surveillance and management of late speech/swallowing sequelae in survivorship clinics.
3:30pm – 4:20pm Proffered Papers 3: Cancer Biology/Skin
Moderators: Devraj Basu, MD, PhD, FACS & Samir Khariwala, MD
(S013) EXOSOMES FROM PRIMARY TUMOR CULTURED FROM HPV+ AND HPV- OROPHARYNGEAL CANCER DEMONSTRATE DIFFERENTIAL EXPRESSION OF MIR INVOLVED IN EMT
Vivian F Wu, MD, MPH; David Dai, PhD; HFHS
(S014) 12-MONTH SMOKING CESSATION PROGRAM LOWERS SOLUBLE CD44 LEVELS IN A HIGH-RISK POPULATION
Drew H Smith, MD, MS1; Shahm Raslan2; Isildinha M Reis, PhD1; Huaping Liu1; Jerri Halgowich1; Claudia Gordon1; Elizabeth J Franzmann, MD1; 1University of Miami Leonard Miller School of Medicine; 2Florida International University Herbert Wertheim College of Medicine
(S015) CRISPR-MEDIATED EPIGENETIC EDITING IDENTIFIES GENE REPRESSION PATTERNS IN HPV+ HEAD AND NECK CANCER AND MODULATES CELL GROWTH
Andrey Finegersh; Koji Ebisumoto; Sayed Sadat; Joseph Califano; UCSD
(S016) COMPARISON OF THE 40-GENE EXPRESSION PROFILE TEST WITH CLINICOPATHOLOGIC RISK FACTOR-BASED ASSESSMENT TO IMPROVE METASTASIS RISK ASSESSMENT IN CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Jason G Newman, MD1; Ashley Wysong, MD2; Mary A Hall, PhD3; Christine N Bailey, MPH3; Kyle R Covington, PhD3; Sarah J Kurley, PhD3; Robert W Cook, PhD3; Chrysalyne D Schmults, MD4; Sarah T Arron, MD, PhD5; 1University of Pennsylvania Health System, Philadelphia, PA; 2University of Nebraska Medical Center, Omaha, NE; 3Castle Biosciences, Inc.; 4Brigham and Women’s Hospital, Boston, MA; 5University of California San Francisco, San Francisco, CA
(S017) TARGETING CHEMOKINE (C-X-C MOTIF) LIGAND 17 (CXCL17) IN CUTANEOUS SQUAMOUS CELL CARCINOMA
Rafay Q Soleja, MD; Emily Zimmerman, BS; Manon Doucet; Gauri Shishodia, PhD; Tara Moore-Medlin, BS; Cherie-Ann O Nathan, MD; Alok R Khandelwal, PhD; LSU Health Sciences Center
(S018) INVASION RATIO: A POTENTIAL NOVEL PROGNOSTIC METRIC FOR RISK-STRATIFYING PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Moran Amit, MD, PhD; Gleber N Frederico, PhD; The University of Texas MD Anderson Cancer Center
4:40pm – 5:30pm Video Session: Experts in Surgical Technique – Thyroid and Parathyroid

Moderators: Susan McCammon, MD
Speakers & Schedule:

Introduction – Susan McCammon, MD 4:40 pm – 4:45 pm
Case 1 with Video – Lisa Orloff, MD, FACS, FACE 4:45 pm – 4:55 pm
Case 2 with Video – Maisie Shindo, MD 4:55 pm – 5:05 pm
Discussion and Commentary – Amy Chen, MD, MPH 5:05 pm – 5:20 pm
Question and Answer – All Panelists 5:20 pm – 5:30 pm

Description:
This will be a case-based panel discussion. We will use video clips to illustrate clinical cases using novel image guidance or tissue localization techniques in thyroid and parathyroid surgery.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Evaluate traditional and evolving techniques for tissue localization in thyroid and parathyroid surgery.
  • Develop an algorithm for utilizing image guidance in central compartment neck dissection.
  • Choose appropriate methods to enhance parathyroid identification and preservation during thyroid and parathyroid surgery.
4:40pm – 5:30pm Proffered Papers 4: Function/Quality/Reconstruction
Moderators: Alexandra E. Kejner, MD, Rhorie Kerr, MD, & Giovana R. Thomas, MD
(S019) MODELING HOUSEHOLD ECONOMIC STRAIN ASSOCIATED WITH HEAD AND NECK CANCER TREATMENT: UTILIZING DATA FROM THE FEDERAL RESERVE BOARD SURVEY OF HOUSEHOLD ECONOMICS AND DECISION-MAKING
Suparna Shah, MD1; Vivek Pandrangi, MD1; Gabriela Lilly, MD1; Matthew Herman, MSc2; Ryan Li, MD1; 1Oregon Health and Science University; 2ExodusPoint
(S020) LARYNGEAL CANCER TREATMENT DECISION MAKING: A CONJOINT ANALYSIS OF GENERAL PUBLIC ATTITUDES AND PRIORITIES
Montana Upton, MD1; Neha Reddy, BA2; Mamdouh Aker, BA2; Kevin James, BA2; Marilene Wang, MD2; Abie H Mendelsohn, MD2; 1Vanderbilt University Department of Otolaryngology – Head and Neck Surgery; 2UCLA Department of Head and Neck Surgery
(S021) PHARYNGO-ESOPHAGEAL COMPLICATIONS OF ANTERIOR CERVICAL SPINE SURGERY: A MULTI-CENTER REVIEW OF EVALUATION AND MANAGEMENT
Rula Mualla, MD1; Matt Hanasono, MD2; Mauricio Moreno, MD3; Mark Wax, MD, FACS, FRCS1; Larissa Sweeney, MD4; Andrew Holcomb5; Zhen Gooi, MD6; Andrew Huang, MD, FACS7; Ryan Jackson, MD8; Patrik Pipkorn, MD8; Jamie Ku, MD9; Jeremy Richmon, MD5; Ryan Li, MD, FACS1; 1OHSU; 2MD Anderson; 3University of Arkansas; 4LSU; 5Mass Eye and Ear; 6University of Chicago; 7Baylor; 8Washington University St. L.; 9Cleveland Clinic
(S022) INTRAOPERATIVE VASOPRESSORS IN HEAD AND NECK FREE FLAPS: EFFECT ON REOPERATION RATES
James R Gardner; Victoria Gau, MD; Patrick Page, MD; Deanne King, MD, PhD; Emre Vural, MD; Jumin Sunde, MD; Mauricio Moreno, Md; University of Arkansas for Medical Sciences
(S023) RATES OF BONE REABSORPTION AND NONUNION IN THE RECONSTRUCTION OF THE MANDIBLE USING OSTEOCUTANEOUS RADIAL FOREARM FREE FLAP.
Omar A Karadaghy, MD, MSCI1; Benjamin , MD1; Caroline Mussatto, BS2; Taylor Norris2; Nick Harn, MD, PhD1; Andres Bur, MD1; 1University of Kansas Medical Center; 2University of Kansas School of Medicine
(S024) IMPACT OF PREOPERATIVE AND INTRAOPERATIVE MANAGEMENT ON OUTCOMES IN OSTEONECROSIS REQUIRING FREE FLAP RECONSTRUCTION
Erica E Mayland, MD1; Brian P Swendseid, MD2; Joseph M Curry, MD2; Alexandra E Kejner, MD3; Carissa M Thomas, MD, PhD4; Joshua J Kain, MD4; Steve B Cannady, MD5; Kendall Tasche, MD5; Eben L Rosenthal, MD6; Michael DiLeo, MD7; Caitlin McMullin, MD8; Brett Miles, MD1; Rocco M Ferrandino, MD1; Juliana Rantisi, BS9; Mark K Wax, MD9; Larissa Sweeny, MD7; 1Icahn School of Medicine at Mount Sinai; 2Thomas Jefferson University; 3University of Kentucky; 4University of Alabama at Birmingham; 5University of Pennsylvania Health System; 6Stanford University; 7Louisiana State University Health Science Center – New Orleans; 8H. Lee Moffitt Cancer Center & Research Institute; 9Oregon Health and Science University School of Medicine
5:30pm – 6:30pm Industry Symposia – Merck & Gardasil9
All Times Listed in Central Time Session Title
7:30 – 8:30 am Milton J. Dance Symposium: Survivorship and Late Effects

Moderators: Michael Moore, MD
Panelists: Heather Starmer, MA, Bruce Neustadter, Carolyn Dee, Marci Nilsen, PhD, MSN, RN, Joel Epstein, DMD, MSD Rosemary Martino, PhD
Schedule:

Welcome and Introduction – Michael Moore, MD 7:00 am – 7:07 am
Oral Care in Head and Neck Survivorship – Joel Epstein, DMD, MSD 7:07 am – 7:17 am
Improving Swallowing and Quality of Life in Head and Neck Cancer Patients – Rosemary Martino, PhD 7:17 am – 7:30 am
Roundtable Case-Based Discussion – All Panelists 7:30 am – 8:25 am
Summary and Wrap Up – – Michael Moore, MD 8:25 am – 8:30 am

Description:
This session will outline what is currently known about the goals and relative priorities of head and neck cancer patients who have underwent treatment. Specific cases with real head and neck cancer survivors will be used to highlight common treatment-related side effects and approaches that can be used to help reduce short and long term toxicity.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Recognize common treatment-related side effects that impact head and neck cancer survivors.
  • Observe the relative priority survivors place on head and neck cancer cure compared to side effects from treatment.
  • Outline techniques that can be used to mitigate toxicity from head and neck cancer therapy.
8:45am – 9:30am Christopher O’Brien Lecture –
Suzanne Topalian, MD
Dr. Topalian is the Bloomberg~Kimmel Professor of Cancer Immunotherapy, and a Professor of Surgery and Oncology at the Johns Hopkins University School of Medicine. She is the director of the Melanoma Program in the Sidney Kimmel Comprehensive Cancer Center, and is an associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins. Dr. Topalian is a physician-scientist whose studies of anti-tumor immunity have been foundational in developing cancer immunotherapy. She received her medical and scientific training at Tufts University School of Medicine, Thomas Jefferson University Hospital, and the National Cancer Institute. She joined the Johns Hopkins Kimmel Cancer Center in 2006 as the inaugural director of its Melanoma Program. Her current research focuses on manipulating “immune checkpoints” such as PD-1 in cancer therapy, discovering biomarkers predicting response and resistance, and developing effective treatment combinations. Dr. Topalian’s work is widely recognized: she was named one of Nature’s 10 in 2014, and received the Karnofsky Award from ASCO in 2015, the Taubman Prize in 2016, and the NCI’s Rosalind E. Franklin Award in 2018, for landmark discoveries in cancer immunotherapy. Dr. Topalian was elected to the National Academy of Medicine in 2017. Her work has opened new avenues of scientific investigation and has established immunotherapy as a pillar of oncology.
9:45am – 10:30am Closing Comments (NO CME)
Jim Kelly
Jim Kelly is a three-time head and neck cancer survivor and a Pro Football Hall of Famer. He led his team to six AFC East Championships and four consecutive championship appearances and holds the all-time professional football record for most yards gained per completion in a single game. Jim founded the Hunter’s Hope Foundation in 1997 following his son’s Krabbe disease diagnosis, which took his life in 2005. Jim was first diagnosed with head and neck squamous cell carcinoma in 2013 and has been a Your Cancer Story spokesperson since 2017.
10:30am – 11:00am Break
11:00am – 12:20pm HPV: Epidemiology, Behavior, Prevention and Clinical Implications

Moderators: Carole Fakhry, MD, MPH
Speakers & Schedule:

Epidemiology of HPV-related Cancer – Beth Beadle 11:00 am – 11:20 am
Primary and Secondary Prevention of HPV-associated Oropharynx Cancer – Joseph Califano, MD, FACS 11:20 am – 11:40 am
Clinical Implications of HPV-positive Tumor Status: Treatment, Trials and Common Questions – Robert Haddad, MD 11:40 am – 12:00 pm
Question and Answer – All Panelists 12:00 pm – 12:20 pm

Description:
This session will review updates in the epidemiology of HPV, HPV-related cancers, prevention strategies and their clinical implications.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Discuss the nuances in HPV epidemiology.
  • Convey the unknowns and limitations of prevention in the current landscape.
  • Explain the prognostic implications of HPV, trial options and clarify behavioral questions.
Innovations in Head and Neck Cancer Treatment – Immunotherapy to New Robotics (Thyroid Ablation, Neoadjuvant Immunotherapy, Imaging, etc)

Moderators: Nishant Agrawal, MD, FACS
Speakers & Schedule:

Imaging Innovation for Intraoperative Detection of Cancer – Max Witjes, MD, DDS, PhD 11:00 am – 11:20 am
Novel Interventions for Thyroid Cancer – Ralph Tufano, MD 11:20 am – 11:40 am
Innovation in Robotics for Transoral Surgery – Snehal Patel, MD, FFRCS 11:40 am – 12:00 pm
Novel Diagnostic and Therapeutic Options for Head and Neck Cancer – Nishant Agrawal, MD, FACS 12:00 pm – 12:20 pm

Description:
We will discuss innovations in intra-operative imaging, novel interventions for thyroid cancer, robotics for transoral surgery, and novel treatments for head and neck cancer.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Understand the impact of high definition microendoscopy, autofluorescence, contrast agents, and radiolabeled agents for detection of cancer during surgical procedures.
  • Understand novel approaches in the management of differentiated thyroid cancer.
  • Understand the limitations of current robotic technology and explore future innovations in robotic technology.
12:20pm – 1:00pm Break
1:00pm – 1:50pm How Would You Reconstruct this Defect? Controversies Regional & Free Flap Options

Moderators: Urjeet Patel, MD, FACS
Speakers & Schedule:

Total Glossectomy Defects – Derrick Lin, MD 1:00 pm – 1:06 pm
Total Glossectomy Case Discussion – Urjeet Patel, MD, FACS 1:06 pm – 1:13 pm
Lateral Mandible Defects +/- Condyles – Peter Dziegielewski, MD, FRCSC 1:13 pm – 1:19 pm
Lateral Mandible Case Discussion – Urjeet Patel, MD, FACS 1:19 pm – 1:26 pm
Lateral Skull Base Defects – Matthew Spector, MD 1:26 pm – 1:32 pm
Lateral Skull Base Case Discussion – Urjeet Patel, MD, FACS 1:32 pm – 1:39 pm
Question and Answer – All Panelists 1:39 pm – 1:50 pm

Description:
We will use a brief presentation followed by case presentation and discussion format to discuss options and controversies surrounding regional and free flap reconstruction. The three specific defects that will be discussed are total glossectomy, lateral mandible including condyle, and lateral skull base.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Recognize the functional and cosmetic implications of these 3 defects.
  • Distinguish advantages and disadvantages of various regional and free flap reconstructive options for these 3 defects.
  • Formulate optimal and patient-specific treatment plans for patients with such defects.
Proffered Papers 5: Endocrine/Salivary
Moderators: Seungwon Kim, MD, Julia Noel, BS, MD, David Charles Shonka, MD
(S025) PREVALENCE AND RISK FACTORS FOR MULTIFOCALITY IN PEDIATRIC THYROID CANCER: A MULTICENTER STUDY
Grace L Banik, MD1; Maisie L Shindo, MD2; Kristen L Kraimer, MD2; Katherine Manzione3; Abhita Reddy, MD4; Ken Kazahaya, MD, MBA5; Andrew J Bauer, MD6; Jeffrey C Rastatter, MD4; Mark E Zafereo, MD7; Steven G Waguespack, MD8; Daniel C Chelius, Jr, MD9; Lourdes Quintanilla-Dieck, MD2; 1Division of Pediatric Otolaryngology, Children’s Hospital of Philadelphia; 2Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University; 3Department of Statistics, Colorado State University; 4Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann & Robert H. Lurie Children’s Hospital of Chicago; 5Division of Pediatric Otolaryngology, Children’s Hospital of Philadelphia, Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania; 6Division of Endocrinology and Diabetes, Children’s Hospital of Philadelphia; 7Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center; 8Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center; 9Division of Otolaryngology-Head and Neck Surgery, Texas Children’s Hospital
(S026) EVALUATION OF INTRAOPERATIVE PARATHYROID HORMONE LEVELS AND EFFECTS ON OPERATIVE SUCCESS
Brody King, BS1; Hilary C McCrary, MD, MPH2; Vanessa Torrecillas, MD2; Devaprabu Abraham, MD3; Jason P Hunt, MD2; 1University of Utah School of Medicine; 2University of Utah School of Medicine – Division of Otolaryngology – Head and Neck Surgery; 3University of Utah School of Medicine, Department of Internal Medicine
(S027) LARYNGEAL ADDUCTOR REFLEX: A BETTER MODALITY OF NERVE MONITORING DURING CENTRAL NECK SURGERY
Mohamed A Aboueisha, MD; Mahmoud Omar, MD; Abdallah S Attia, MD; Deena S Hadedeya, MD; Mohamed Shama, MD, MSc, MRCS, EBSQ; Emad Kandil, MD, MBA, FACS, FACE; Tulane university
(S028) PAROTID GLAND MALIGNANCY: DISCREPANCIES IN STAGING AND OUTCOMES BY SITE OF FACIAL NERVE INVOLVEMENT
Bryan B Hair, BS; Khashayar Arianpour, MD; Shlomo A Koyfman, MD; Brian B Burkey, MD; Eric D Lamarre, MD; Cleveland Clinic Foundation
(S029) ANTI-TUMORIGENIC EFFECTS OF CWP232291, A FIRST-IN-CLASS INHIBITOR OF BETA-CATENIN/WNT PATHWAY IN ADENOID CYSTIC CARCINOMA.
Joseph O Humtsoe1; Hyun-su Kim1; Leilani Jones1; Bhumsuk Keam2; Patrick Ha1; 1Department of Otolaryngology- Head and Neck Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.; 2Department of Internal Medicine, Seoul National University, Seoul, Korea.
(S030) EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH ADVANCED TRK FUSION SALIVARY GLAND CANCER
Xiuning Le1; Christina Baik2; Jessica Bauman3; Marcia S Brose4; Jill Gilbert5; Juneko E Grilley-Olson6; Jennifer M Johnson7; Ray McDermott8; Tejas Patil9; Luis E Raez10; Makoto Tahara11; John Reeves12; Laura Dima12; Nicoletta Brega12; Alexander Drilon13; David S Hong1; 1University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA; 3Department of Hematology/Oncology at Fox Chase Cancer Center, Philadelphia, PA, USA; 4Abramson Cancer Center of the University of Pennsylvania School of Medicine, Philadelphia, PA, USA; 5Vanderbilt University, Nashville, TN, USA; 6University of North Carolina Lineberger Cancer Center, Chapel Hill, NC, USA; 7Thomas Jefferson University and Sidney Kimmel Cancer Center, Philadelphia, PA, USA; 8St. Vincent’s University Hospital and Cancer Trials Ireland, Dublin, Ireland; 9Department of Medicine, Division of Medical Oncology, University of Colorado, Denver, Aurora, CO, USA; 10Memorial Cancer Institute, Florida International University, Miami, FL, USA; 11National Cancer Center Hospital East, Kashiwa, Japan; 12Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA; 13Memorial Sloan Kettering Cancer Center, New York, NY, USA
2:10pm – 3:00pm Management of Late Stage Oral Cavity Tumors

Moderators: Jonathan Irish, MD, MSc, FRCSC, FACS
Panelists: Michael Moore, MD, FACS, Eric Moore, MD, FACS, Barry Wenig, MD
Schedule:

Case Presentation – Jonathan Irish, MD, MSc, FRCSC, FACS 2:10 pm – 2:12 pm
Case Discussion – All Panelists 2:12 pm – 2:22 pm
Case Presentation – Jonathan Irish, MD, MSc, FRCSC, FACS 2:22 pm – 2:24 pm
Case Discussion – All Panelists 2:24 pm – 2:34 pm
Case Presentation – Jonathan Irish, MD, MSc, FRCSC, FACS 2:34 pm – 2:36 pm
Case Discussion – All Panelists 2:36 pm – 2:46 pm
Case Presentation – Jonathan Irish, MD, MSc, FRCSC, FACS 2:46 pm – 2:48 pm
Case Discussion – All Panelists 2:48 pm – 3:00 pm

Description:
We will use a case management format to illustrate the factors that must be considered in the management of late stage oral cancers. The case management presentation will demonstrate the decision making that must be considered in the following scenarios: 1) the young patient with advanced disease, 2) the frail elderly patient, 3) the unresectable patient and 4) the “vulnerable” patient with little social support. The case management format will include factors that need to be considered in tumor ablation, reconstruction and also incorporate multidisciplinary care options that need to be incorporated into the management of the advanced oral cancer patient.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Implement an evidence-based approach to the management of advanced oral cancer in a young healthy patient.
  • Recognize how the treatment of advanced oral cancer is modified in 1) the elderly and frail patient 2) patients with unresectable disease and 3) patient with poor social supports.
  • Convey the importance of multidisciplinary discussion and approaches to the ablative and reconstructive management of the patient with advanced oral cancer.
Proffered Papers 6: Education/Oropharynx
Moderators: Babak Givi, MD, Sarah L. Rohde, Tammara Watts, MD, PhD
(S031) THE EFFECTS OF A HEAD AND NECK MULTIDISCIPLINARY CLINIC ON PATIENT SATISFACTION
Ricardo Aulet, Md, MBA1; Christine Chung, MD2; Louis Harrison, MD, FASTRO2; Trad Wadsworth, MD, MBA2; 1UMass Memorial Medical Center; 2Moffitt Cancer Center
(S032) TRENDS IN THE PRESENCE OF WOMEN SPEAKERS AT THE AMERICAN HEAD & NECK SOCIETY MEETINGS FROM 2007-2019
Marianna Hernandez, BA; Amelia Power, MS; Mekibib Altaye, PhD; Chad A Zender, MD; Alice L Tang, MD; University of Cincinnati College of Medicine
(S033) TIME-TO-TREATMENT IN HEAD AND NECK CANCER IS ASSOCIATED WITH INCOME, RACE, AND SEX
Douglas R Farquhar; Wesley Stepp; Siddharth Sheth, MD, MPH; Jeffery Blumberg, MD; Catherine Lumley, MD; Samip Patel, MD; Trevor Hackman, MD; Adam Zanation; Andrew Olshan, PhD; University of North Carolina
(S034) COST-EFFECTIVENESS OF CIRCULATING TUMOR HPV DNA FOR THE SURVEILLANCE OF CANCER RECURRENCE IN HPV-ASSOCIATED OROPHARYNGEAL CANCER
Matthew C Ward, MD1; Gary V Walker2; Benjamin Moeller, MD, PhD1; Shlomo A Koyfman3; Chirag Shah3; 1Levine Cancer Institute, Atrium Health; 2Banner MD Anderson; 3Taussig Cancer Institute, Cleveland Clinic
(S035) VALIDATION OF NRG ONCOLOGY’S PROGNOSTIC NOMOGRAMS FOR OROPHARYNGEAL CANCER IN THE VETERANS AFFAIRS DATABASE
Tyler J Nelson, BS1; Abhishek Kumar, MD1; Jingjing Zou, PhD2; Caroline A Thompson, PhD3; Casey Williamson, MD1; Prangrawee Sangchan, MD4; Lucas Vitzthum, MD5; Andrew Sharabi, MD1; James Murphy, MD, MPH1; Carole Fakhry, MD6; Loren K Mell, MD1; 1Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California; 2Department of Family Medicine and Public Health and Department of Mathematics, University of California San Diego, La Jolla, California; 3Division of Epidemiology, San Diego State University School of Public Health, San Diego, California; 4Division of Radiation Oncology, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand; 5Department of Radiation Oncology, Stanford University; 6Department of Otolaryngology, Johns Hopkins University
(S036) ADJUVANT RADIATION VS CHEMORADIATION IN HPV+ OROPHARYNGEAL SQUAMOUS CELL CARCINOMA WITH EXTRANODAL EXTENSION
Samer T Elsamna, BA; Ghayoour Mir, DO; Dylan F Roden, MD, MPH; Rutgers New Jersey Medical School, Department of Otolaryngology—Head & Neck Surgery
3:00pm – 3:30pm Break
3:30pm – 4:20pm NPC and Skull Base Surgery: Complex Case Discussion

Moderators: Ivan El-Sayed, MD
Panelists: Jack Phan, Christine Glastonbury, Nabil Saba, MD, Shirley Su, MBBS, Marc Cohen, MD, MPH
Schedule:

Case Presentation – Ivan El-Sayed, MD 3:30 pm – 3:33 pm
Case Discussion – All Panelists 3:33 pm – 3:45 pm
Case Presentation – Ivan El-Sayed, MD 3:45 pm – 3:48 pm
Case Discussion – All Panelists 3:48 pm – 4:00 pm
Case Presentation – Ivan El-Sayed, MD 4:00 pm – 4:03 pm
Case Discussion – All Panelists 4:03 pm – 4:20 pm

Description:
Challenging cases of skull base malignancy will be presented to an expert panel for discussion. Topics will include diagnostic work up, advances in treatment strategies, the role of organ preservation and immunotherapy, and recognition of a growing number of pathologic variants.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Recognize several key pathologic variants of sinonasal carcinoma and their impact on treatment options.
  • Appraise tumor invasion and extent of disease into the orbit and skull base.
  • Discuss surgical, radiation, and systemic treatment options for patients with skull base cancer.
Proffered Papers 7: Oral Cavity Plus
Moderators: Ameya Ajit Asarkar, Trinitia Cannon, MD, & Tamer Ghanem, MD, PhD
(S037) ORAL CAVITY SQUAMOUS CELL CARCINOMA TUMOR CENTER AND LEADING EDGE HAVE A TEMPORALLY STABLE, UNIQUE MICROBIOME COMPARED TO CONTRALATERAL NORMAL SITES
Carissa M Thomas, MD, PhD1; Alya Heirali, PhD2; Hedyeh Ziai, MD3; Maria Kulikova, BS, DPT2; Carolyn Barsoum, BS, MA3; Feben Alemu3; Dale Brown, MB3; John R de Almeida, MD, MSc3; David Goldstein, MD, MSc3; Patrick Gullane, MB3; Ralph Gilbert, MD3; Jonathan Irish, MD, MSc3; Douglas Chepeha, MD, MSCPH3; Bryan Coburn, MD, PhD2; 1University of Alabama at Birmingham; 2Toronto General Research Institute; 3University Health Network, University of Toronto
(S038) IDENTIFICATION OF OCCULT METASTATIC DISEASE VIA LYMPHOSCINTIGRAPHY GUIDED NECK DISSECTION (LSG-ND) IN N0 ORAL SQUAMOUS CELL CARCINOMA
Lisa B Earnest-Noble, MD, PhD; Rachel Lipsky; William I Kuhel, MD; David I Kutler, MD; Weill Cornell Medicine
(S039) PROTEIN BIOMARKERS AS INDEPENDENT PREDICTORS OF PROGNOSIS AND CLINICOPATHOLOGIC OUTCOMES IN ORAL CAVITY SQUAMOUS CELL CARCINOMA
Daniel J Lee, MD; Nitin Pagedar, MD; Anand Rajan, MBBS, MD; Marisa Buchakjian, MD, PhD; Steven Sperry, MD; University of Iowa
(S040) THE SUBSTANTIAL OMISSION OF INDICATED POST-OPERATIVE RADIOTHERAPY IN ADVANCED STAGE ORAL CANCER IN THE UNITED STATES: A CALL TO ACTION
Musaddiq Awan, MD1; Ken Akakpo, MD1; Becky Massey, MD1; Michael Stadler, MD1; Bruce Campbell, MD1; Monica Shukla, MD1; Christopher Schultz, MD1; Aditya Shreenivas, MD1; Stuart Wong, MD1; Evan Graboyes, MD, MPH2; Patrik Pipkorn, MD, MSCI3; Sidharth V Puram, MD, PhD3; Joseph Zenga1; 1Medical College of Wisconsin; 2Medical University Of South Carolina; 3Washington University School of Medicine
(S041) COMPARISON OF 89ZR-PANITUMUMAB PET/CT AND FDG-PET/CT FOR PREOPERATIVE IDENTIFICATION OF METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Yu-Jin Lee, MD; Nynke S van den Berg, PhD; Marisa Hom, PhD; Heying Duan; Carmen Azevedo; Valentina Ferri; Brock Martin, MD; Roan Raymundo; Jessa Castillo; Bin Shen, PhD; Michael J Kaplan, MD; Alexander D Colevas, MD; Frederick Chin, PhD; Fred Baik, MD; Andrei Iagaru, MD; Eben L Rosenthal; Stanford University
(S042) BENEFIT OF ADJUVANT CHEMOTHERAPY IN SURGICALLY RESECTED, NEGATIVE MARGIN HEAD AND NECK CANCER WITH PATHOLOGICALLY CONFIRMED EXTRANODAL EXTENSION
Ghayoour Mir, DO; Gregory L Barinsky, PharmD; Roman Povolotskiy, MD; Soly Baredes, MD; Boris Paskhover, MD; Richard C Park, MD; Dylan F Roden, MD, MPH; Rutgers New Jersey Medical School
4:40pm – 5:30pm Video Session: Experts in Surgical Technique – Salivary and Reconstruction

Moderators: David Eisele, MD
Speakers & Schedule:

Complex Parotid Neoplasm Case Presentation – David Eisele, MD 4:40 pm – 5:00 pm
Complex Parotid Neoplasm Case Presentation – M. Boyd Gillespie, MD, MS 5:00 pm – 5:15 pm
Reconstruction of Complex Parotid Defect – Ralph Gilbert, MD 5:15 pm – 5:30 pm

Description:
We will use a case management format to discuss the management of complex parotid neoplasms . Surgical approaches and reconstruction techniques will be presented.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Assess the patient with a complex parotid neoplasm.
  • Understand the surgical complexities of surgical resection of recurrent parotid neoplasms.
  • Know the options for surgical reconstruction following radical parotidectomy.
Proffered Papers 8: Oropharynx
Moderators: Thomas Julian Ow, MD, Eleni M. Rettig, MD, & Shaum S. Sridharan
(S043) TRANSORAL ROBOTIC SURGERY (TORS) VERSUS PRIMARY RADIOTHERAPY IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA: AN UPDATED COMPARATIVE SURVIVAL ANALYSIS USING A LARGE POPULATION DATABASE.
Mitchell Flagg; Bharat Panuganti, MD; Rohith Voora, BS; Joseph Califano, MD; Ryan Orosco, MD; UCSD School of Medicine
(S044) EXTRANODAL EXTENSION ON PRESENTATION, TREATMENT, AND OUTCOMES OF OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Neel Sangal, MD; Justin Shinn; Leila Mady, MD, MPH, PHD; David Shimunov, BA; Karthik Rajasekaran; Steven Cannady, MD; Ara Chalian, MD; Christopher H Rassekh, MD; Devraj Basu, MD; Jason Newman, MD; Gregory Weinstein, MD; Robert Brody, MD; Hospital of the University of Pennsylvania
(S045) OUTCOMES OF POSTSURGICAL P16+ OROPHARYNGEAL CARCINOMA WITH HIGH RISK FEATURES TREATED WITH ADJUVANT RADIATION VERSUS ADJUVANT CHEMORADIATION
Jordan B Fenlon, MD; Ryan J Hutten, MD; Chris R Weil, MD; Shane Lloyd, MD; Ying J Hitchcock, MD; Huntsman Cancer Institute – University of Utah Health
(S046) SUPRAHYOID AND LATERAL PHARYNGOTOMY FOR MANAGEMENT OF OROPHARYNGEAL SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW AND THE MAYO CLINIC EXPERIENCE.
Joseph N Badaoui, MD; Linda X Yin, MD; Christine M Lohse, MS; Daniel L Price, MD; Jan L Kasperbauer, MD; Eric J Moore, MD; Daniel B Noel, MD; Kerry D Olsen, MD; Kathryn M Van Abel, MD; Mayo Clinic, Rochester, Minnesota
(S047) THE EFFECT OF SARCOPENIA ON ONCOLOGIC OUTCOMES OF PRIMARY SURGERY OR DEFINITIVE RADIATION THERAPY IN LOCALIZED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Brennan Olson; Jared Edwards; Lucas Stone; Angie Jiang; Xinxia Zhu; John Holland, MD; Ryan Li, MD; Peter Andersen, MD; Stephanie Krasnow, PhD; Daniel Marks, MD, PhD; Daniel Clayburgh, MD, PhD; OHSU
(S048) THE ROLE OF ADJUVANT CHEMOTHERAPY IN HIGH RISK HPV-POSITIVE OROPHARYNGEAL CANCER
Clifford Chang1; Michelle Chen2; Steven B Chinn2; 1NYU School of Medicine; 2University of Michigan – Department of Otolaryngology – Head and Neck Surgery
5:30pm – 7:00pm Industry Symposia
7:00pm – 8:00pm President’s Reception
All Times Listed in Central Time Session Title
8:00am – 12:45pm Advance Practice Provider Symposium

Moderators: Ellie Maghami, MD and Deepa Shah, PA-C
Schedule & Faculty:

Introduction – Ellie Maghami, MD and Deepa Shah, PA-C 8:00am – 8:15am
Preparing Patients with Advanced Stage Head and Neck Cancer for Surgery – Trina Sheedy, PA 8:15am – 8:45am
Managing Adverse Events following Head and Neck Surgery: A Review in Post-Operative Care for the Advanced Practice Provider – Deepa Shah, PA-C, Brittni Carnes, Lily Lam and Monica Kurzymski 8:45am – 9:25am
Communication Skills for Engaging with Difficult Patient Behaviors – Laura Kirk, PA 9:25am – 9:55am
The Integrated Visit: Collaborating with Speech and Language Pathologists – Cara Evans 9:55am – 10:25am
Break 10:25am – 10:45am
Evidence and Dogma: Pretreatment Imaging for Head and Neck Cancer Patients – Hilda Stambuk, MD 10:45am – 11:15am
Survivorship Care in Head and Neck Cancer – Jonas Johnson, MD, Marci Nilsen, PhD, MSN, RN, Casey Fazer, MD, and Brittni Carnes 11:15am – 12:15pm
Question and Answer – All Panelists 12:15pm – 12:45pm

Description:
The inaugural APP program is the society’s tribute to the fundamental role APPs have within the multidisciplinary care team and the contributions of allied health personnel in general to the betterment of head and neck cancer care. This year’s meeting focuses on survivorship through quality and innovation and the APP program will aim to address this theme. Come join us in Chicago, meet colleagues, expand your knowledge, identify opportunities for professional advancement and collaboration.
Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Run a survivorship clinic.
  • Effectively communicate.
  • Manage adverse effects after head and neck surgery.
8:30am – 11:30am Current Concepts in Speech and Swallow Management in Head and Neck Cancer

Moderators: Nishant Agrawal, MD, FACS, Katherine Hutcheson, MD, Dinesh Chhetri, MD, and Rosemary Martino, PhD
Schedule & Faculty:

Rehabilitation of Articulation and Swallowing – Nishant Agrawal, MD, FACS 8:30am -9:15am
Functional Considerations of Surgical Management – Ryan Li 8:30am – 8:40am
Postsurgical Oral Rehabilitation: Comparing Therapy Models and Integration of Biofeedback – Carly Barbon, PhD 8:40am – 8:50am
Oral Reconstruction – Jamie Ku, MD, BS 8:50am – 9:00am
Question and Answer – All Panelists 9:00am – 9:15am
Oropharynx: TORS/TOLS for Oropharynx Cancer – Case-Based Patient Selection, Outcomes and Postsurgical Pathways – Katherine Hutcheson, MD 9:15am – 10:00am
ORATOR – Anthony Nichols, MD, BSc, FACS 9:15am – 9:22am
SALT TORS/TLMS Survey – Katherine Hutcheson, MD 9:22am – 9:29am
TOLS (v TORS) functional implications and PATHOS – Bruce Haughey, MBChB FACS FRACS 9:29am – 9:36am
US Surgery Perpsective – Neil Gross, MD, FACS 9:36am – 9:42am
Question and Answer – All Panelists 9:42am – 10:00am
Larynx: Optimizing Post-Laryngectomy Function – Case Based Recon, Patient Selection, Prosthetics/TEP Procedures – Dinesh Chhetri, MD 10:00am – 10:45am
Case Presentation – Daniel Deschler, MD, FACS 10:00am – 10:45am
Case Presentation – Mauricio Moreno, MD 10:00am – 10:07am
Case Presentation – Barbara Ebersole 10:07am – 10:14am
Case Presentation – Heather Starmer, MA 10:14am – 10:21am
Case Discussion and Question and Answer – All Panelists 10:21am – 10:28am
Advances in Dysphagia Management – Blitz of Innovations on the Horizon? – Rosemary Martino, PhD 10:28am – 10:45am
Apps – Heather Starmer, MA 10:45am – 10:53am
Manometry – Timothy Mcculloch, MD 10:53am – 11:01am
Surgical Innovations – Brandon Baird, MD 11:01am – 11:09am
Question and Answer – All Panelists  11:09am – 11:30am

Description:
This course will cover current concepts in speech and swallow management in head and neck cancer including:

  • Oral cavity cancer, how its treatment can adversely affect speech/articulation and swallowing and reconstructive and rehabilitation strategies to restore function.
  • Functional outcomes used at the forefront of clinical decision making and management of oropharyngeal cancer to discuss patient selection, functional outcomes, and speech pathology pathways after transoral surgery.
  • The difficulties of management of voice prosthesis and optimal voicing through case presentations and group discussion.
  • An introduction to four evidence-based innovations targeting dysphagia that are on the horizon for HNC survivors. Each innovation will be described and briefly demonstrated by the investigator leading its development.

Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Recognize reconstructive and rehabilitation strategies to restore function.
  • Understand patient selection, functional outcomes, and speech pathology pathways after transoral surgery for oropharyngeal cancer.
  • Address management of voice prosthesis and optimal voicing.
  • Understand innovations targeting dysphagia that are on the horizon for HNC survivors.
12:30pm – 3:40pm International Primer Course on Endocrine Surgery

Moderators: Joseph Scharpf, MD, FACS, Brendan Stack, MD, Gregory Randolph, MD, and David Terris, MD, FACS, FACE
Panelists: Marika Russell, MD, David Shonka, MD, Ayaka Iwata, MD, MS, BA, MS, Michael Singer, Maisie Shindo, MD, Joseph Scharpf, MD, FACS, David Terris, MD, FACS, FACE, Alfred Simental, MD, FACS, Emad Kandil, MBBCh, FACS, Mark Zafereo, MD, Ellie Maghami, MD, David Shonka, MD
Schedule & Speakers:

Welcome – Joseph Scharpf, MD, FACS, Brendan Stack, MD, and Gregory Randolph MD 12:30pm -12:35pm
Surgical Anatomy of the Thyroid and Parathyroid Glands – Joseph Scharpf, MD, FACS, FACE 12:30pm -12:55pm
Work Up of a Patient with a Thyroid Nodule – FNA and Molecular Markers – Marika Russell, MD 12:55pm – 1:15pm
Thyroid Carcinoma – Basics of Pathology and NIFTP – David Shonka, MD 1:15pm – 1:35pm
Postoperative Complications Avoidance and Management – Ayaka Iwata, MD, MS, BA, MS 1:35pm – 1:55pm
Break/Discussion 1:55pm – 2:10pm
Parathyroid Anatomy and Physiology – The Essentials – Michael Singer,  2:10pm – 2:30pm
Work Up of the Patient with an Elevated Serum Calcium – Maisie Shindo, MD 2:30pm – 2:50pm
Parathyroidectomy – Pearls and Pitfalls – David Terris, MD, FACS, FACE 2:50pm – 3:10pm
Panel: Thyroid /Parathyroid – All Panelists 3:10pm – 3:40pm

Description:
Endocrine neck surgery involves a separate knowledge and skill set within head and neck surgery. AHNS member’s practices contain a large and increasing volume of endocrine surgical disease. To serve our AHNS membership we have put together a primer program to cover the field with state of the art presentations by renown AHNS endocrine surgery section faculty that are both expert and diverse. The focus, as a primer, is on the basics of anatomy, related embryology and key surgical maneuvers to optimize surgical care for our thyroid and parathyroid patients.

Learning Objectives:
At the conclusion of this session, attendees will be able to:

  • Cover the essential elements of the anatomic and embryologic basis of thyroid and parathyroid surgery.
  • Provide the key elements necessary in the preop workup of both thyroid and parathyroid patients prior to surgery.
  • Integrate these concepts in case based presentations with audience Q and A input during our Primer Cased based panel.